
Vertex Pharmaceuticals
VRTX · NASDAQ · Biotechnology
Quotes delayed up to 15 min. Updated 16 Nov, 16:00 New York time
- Market cap
- $142 bn
- Div. yield
- —
- Year to date
- +18,8%
Ratio score
based on 9 metrics as of 16.11.2026 ·
Verdict by our methodology based on current metrics. Not an investment recommendation.
Key metrics
5 ✓ · 3 — · 1 ✕ · 1 n/a · hover over a row or tap it to see the trend
All metrics
| Metric | Value | 5-year median | Industry median |
|---|---|---|---|
| P/E TTM | 33,7 | 26,2 | 42,1 |
| Forward P/E | 27,2 | — | 18,7 |
| PEG | 3,0 | — | 4,1 |
| P/S | 10,3 | 9,5 | 6,6 |
| EV/EBITDA | 29,6 | 19,6 | 28,2 |
| P/FCF | 41,9 | — | 26,0 |
| P/B | 6,4 | 6,0 | 9,8 |
Industry median — across 6 profitable companies in “Biotechnology” in Ratio. Revenue and EPS forecasts for future years and the number of employees are in the paid data plan.
Price chart
Compare with
Choose a stock
Closing prices adjusted for splits and dividends. The S&P 500 index and the intraday chart come later.
Analysts
Ratings, 39 analysts
- Buy
- 32
- Hold
- 6
- Sell
- 1
Beat the EPS forecast in 1 of the last 4 quarters
| Quarter | Estimate | Actual | Surprise |
|---|---|---|---|
| Q3 2026 | 4,88 | 4,76 | Down −2,5% |
| Q2 2026 | 4,83 | 4,73 | Down −2,1% |
| Q1 2026 | 4,40 | 4,47 | Up +1,6% |
| Q4 2025 | 5,17 | 5,03 | Down −2,8% |
Price targets and yearly revenue and EPS forecasts are in the paid data plan. These are analysts' opinions, not our verdict.
Financials in charts
| Metric | Q3'26 | Q2'26 | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 | Q1'24 | Q4'23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 3,44 bn | 3,33 bn | 2,99 bn | 3,19 bn | 3,08 bn | 2,96 bn | 2,77 bn | 2,91 bn | 2,77 bn | 2,65 bn | 2,69 bn | 2,52 bn |
| EPS | 2,56 | 4,31 | 4,02 | 4,64 | 4,20 | 3,99 | 2,49 | 3,53 | 4,01 | −13,92 | 4,21 | 3,71 |
| Margin | 19,0% | 33,0% | 34,5% | 37,3% | 35,2% | 34,8% | 23,3% | 31,4% | 37,7% | −135,8% | 40,9% | 38,5% |
| FCF | 546 m | 1,01 bn | 1,29 bn | 349 m | 1,14 bn | 927 m | 778 m | 492 m | 1,30 bn | −3,82 bn | 1,24 bn | 177 m |
From SEC reports. TTM is the sum of 4 quarters; a year is TTM at the end of the calendar year. Forecast bars are in the paid data plan.
Owners
Ownership structure and major holders (13F filings) are in the paid data plan. They are not part of the score or the traffic light.
Insider trades over 12 months
Over 12 months: no purchases, sales $130 m.
| Name | Amount | Shares | Price |
|---|---|---|---|
| kewalramani reshma6 Nov 2026 · sale | $6,31 m | 11 866 | $531,53 |
| mckechnie duncan2 Jul 2026 · sale | $799 779 | 1 541 | $519,00 |
| tatsis ourania2 Jul 2026 · sale | $787 485 | 1 500 | $524,99 |
| liu joy1 Jul 2026 · sale | $416 244 | 828 | $502,71 |
| bozic carmen18 Jun 2026 · sale | $471 413 | 1 020 | $462,17 |
| bozic carmen5 Jun 2026 · sale | $785 250 | 1 745 | $450,00 |
| liu joy1 Jun 2026 · sale | $364 245 | 828 | $439,91 |
| bozic carmen29 May 2026 · sale | $888 300 | 1 974 | $450,00 |
| bunnage mark e.15 May 2026 · sale | $14 964 | 33 | $453,45 |
| bozic carmen15 May 2026 · sale | $613 971 | 1 354 | $453,45 |
| bozic carmen12 May 2026 · sale | $3,14 m | 6 988 | $450,00 |
| bhatia sangeeta n.4 May 2026 · sale | $134 746 | 318 | $423,73 |
| liu joy1 May 2026 · sale | $469 222 | 1 104 | $425,02 |
| liu joy1 Apr 2026 · sale | $439 288 | 978 | $449,17 |
| bozic carmen27 Mar 2026 · sale | $1,05 m | 2 329 | $450,95 |
SEC Form 4. Titles and trading plans are not in the data. They are not part of the score or the traffic light.
About the company
- Industry
- Biotechnology
- Exchange
- NASDAQ
- Country
- US
- IPO date
- 24 Jul 1991
- Website
- www.vrtx.com
Company description, revenue by segment and region, and the CEO will come later.
Earnings
- Next report
- date not announced
An AI summary of the earnings call will come later.
Peers
| Company | Price | ||||
|---|---|---|---|---|---|
REGNRegeneron Pharmaceuticals | $952,40 | 67★★★★★★★★★would watch | 20,5 | +18,6% | 28,5% |
GILDGilead Sciences | $167,58 | 25★★★★★★★would not consider | — | +6,5% | −12,5% |
MRNAModerna | $215,27 | 22★★★★★★would not consider | — | +13,1% | −110,5% |
AMGNAmgen | $462,32 | 67★★★★★★★★★would watch | 26,8 | +8,2% | 24,1% |
ABBVAbbVie | $294,55 | 72★★★★★★★★★would consider | 50,4 | +10,7% | 15,7% |
Ratio — a score by our methodology, not an investment recommendation.




